Acumen Pharmaceuticals to Stop Sabirnetug Development in Alzheimer's After Phase 2 Trial Failure

Article summary

Acumen Pharmaceuticals is discontinuing the development of its lead clinical candidate, sabirnetug (ACU193), following the failure of a Phase 2 clinical trial to meet its primary endpoint.